Watch More Highlights
Erin Grannan, PharmD, BCOP, of The University of Texas MD Anderson Cancer Center, discusses the phase III DESTINY-Breast03 trial, which compared ado-trastuzumab deruxtecan (T-DXd) with standard-of-care trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Of note, T-DXd demonstrated superior progression-free survival across subgroups of patients previously treated with trastuzumab and a taxane, including those with brain metastases (Abstract GS3-01).